Background: In Behçet’s disease posterior segment involvement is very frequent (about 80%). Macular edema is the most commonly observed complication and is related to reduction of visual acuity. The purpose of the study was to evaluate choroidal involvement during posterior vasculitis due to Behçet’s disease. Methods: Thirty eyes (15 patients) presenting with posterior vasculitis due to Behçet’s disease were studied. All patients had been evaluated with optical coherence tomography (Stratus OCT, Zeiss) to evaluate the retinal thickness (RT) and with standardized 8-MHz A scan echography to determine the retinochoroidal thickness (RCT). Echographic evaluation with 10- and 20-MHz probes was performed in all cases. Results: In 7 eyes (23.3%), both RT and RCT were normal. In 5 eyes (16.6%), they were both increased. In the other 18 eyes (60%), the RCT was increased while the RT was normal, thus indicating a thickening of the choroid alone. No significant correlation was found between choroidal thickness and the presence of vitreal abnormalities. Neither increases in RT nor those in RCT were significantly related to visual acuity. No correlation was found between RT or RCT and pharmacological treatment. Conclu sion: Choroidal inflammation could often play a primary eti- ological role during posterior vasculitis in Behçet’s disease. Echographic detection of choroidal thickening in patients with Behçet’s disease not presenting with retinal alterations or visual symptoms could represent a useful way to detect an early inflammation, in order to start a proper therapy and to influence the final visual prognosis.

Keywords:
Behçet’s disease, Optical coherence tomography, Echography, Choroid, Optic neuritis, Vitreoschisis, Posterior vitreous detachment
1.
Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, Kanawati CA, Ayesh I, Stanford MR, Wallace GR: Factor V Leiden mutation is associated with ocular involvement in Behçet disease. Am J Ophthalmol 1999;128:352–356.
2.
Atmaca LS: Fundus changes associated with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 1989;227:340–344.
3.
Ossoinig KC: Standardized echography: basic principles, clinical applications, and results. Int Ophthalmol Clin 1979;19:127–210.
4.
Bronson NR, Turner FT: A simple B-scan ultrasonoscope. Arch Ophthalmol 1973;90:237–238.
5.
Coleman DJ, Silverman RH, Chabi A, Rondeau MJ, Shung KK, Cannata J, Lincoff H: High-resolution ultrasonic imaging of the posterior segment. Ophthalmology 2004;111:1344–1351.
6.
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, et al: Optical coherence tomography. Science 1991;254:1178–1181.
7.
Drexler W, Sattmann H, Hermann B, Ko TH, Stur M, Unterhuber A, Scholda C, Findl O, Wirtitsch M, Fujimoto JG, Fercher AF: Enhanced visualization of macular pathology with the use of ultrahigh-resolution optical coherence tomography. Arch Ophthalmol 2003;121:695–706.
8.
Drexler W, Morgner U, Ghanta RK, Kartner FX, Schuman JS, Fujimoto JG: Ultrahigh-resolution ophthalmic optical coherence tomography. Nat Med 2001;7:502–507.
9.
Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990;335:1078–1080.
10.
Hogan MJ, Kimura SJ, Thygeson P: Signs and symptoms of uveitis and anterior uveitis. Am J Ophthalmol 1959;47:155–170.
11.
Chan A, Duker JS, Ko TH, Fujimoto JG, Schuman JS: Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography. Arch Ophthalmol 2006;124:193–198.
12.
Cennamo G, Rosa N, Iaccarino G, La Rana A, Pasquariello A: Macula study with standardized echography. Acta Ophthalmol Scand 1996;74:178–181.
13.
Atta HR, Byrne SF: The findings of standardized echography for choroidal folds. Arch Ophthalmol 1988;106:1234–1241.
14.
Gallagher MJ, Yilmaz T, Cervantes-Castañeda RA, Foster CS: The characteristic features of optical coherence tomography in posterior uveitis. Br J Ophthalmol 2007;91:1680–1685.
15.
Charteris DG, Champ C, Rosenthal AR, Lightman SL: Behcet’s disease: activated T lymphocytes in retinal perivasculitis. Br J Ophthalmol 1992;76:499–501.
16.
George RK, Chan CC, Whitcup SM, Nussenblatt RB: Ocular immunopathology of Behcet’s disease. Surv Ophthalmol 1997;42:157–162.
17.
Mullaney J, Collum LMT: Ocular vasculitis in Behcet’s disease: a pathological and immunohistochemical study. Int Ophthalmol 1985;7:183–191.
18.
Matsuda N, Ogura Y, Nishiwaki H, Miyamoto K, Matsubara T, Kiryu J, Honda Y: Visualisation of leukocyte dynamics in the choroid with indocyanine green. Invest Ophthalmol Vis Sci 1996;37:2228–2233.
19.
Atmaca LS, Sonmez PA: Fluorescein and indocyanine green angiography findings in Behçet’s disease. Br J Ophthalmol 2003;87:1466–1468.
20.
Bouchenaki N, Cimino L, Auer C, Tao Tran V, Herbort CP: Assessment and classification of choroidal vasculitis in posterior uveitis using indocyanine green angiography. Klin Monatsbl Augenheilkd 2002;219:243–249.
21.
Kohno T, Miki T, Shiraki K, Kano K, Matsushita M, Hayashi K, De Laey JJ: Subtraction ICG angiography in Harada’s disease. Br J Ophthalmol 1999;83:822–833.
22.
Klaeger A, Tran VT, Hiroz CA, Morisod L, Herbort CP: Indocyanine green angiography in Behçet’s uveitis. Retina 2000;20:309–314.
23.
Cennamo G, Rosa N, Iaccarino G: The diagnosis and management of intraocular inflammation with standardised echography with emphasis on macular thickness; in Thijssen JM, Fledelius HC, Tane S (eds): Ultrasonography in Ophthalmology: Proceedings of the 14th Siduo Congress. Dordrecht, Kluwer Academic Publishers, 1992, pp 177–180.
24.
Lightman S, McDonald WI, Bird AC, Francis DA, Hoskins A, Batchelor JR, Halliday AM: Retinal venous sheathing in optic neuritis: its significance for pathogenesis of multiple sclerosis. Brain 1987;100:405.
25.
Kakehashi A, Kado M, Akiba J, Hirokawa H: Variations of posterior vitreous detachment. Br J Ophthalmol 1997;81:527–532.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.